CLARITIN LIQUID CAPSULES
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
10-05-2019
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
LORATADINE
から入手可能:
BAYER INC
ATCコード:
R06AX13
INN（国際名）:
LORATADINE
投薬量:
10MG
医薬品形態:
CAPSULE
構図:
LORATADINE 10MG
投与経路:
ORAL
パッケージ内のユニット:
24/36/84
処方タイプ:
OTC
治療領域:
SECOND GENERATION ANTIHISTAMINES
製品概要:
Active ingredient group (AIG) number: 0120416001; AHFS:
認証ステータス:
APPROVED
承認日:
2014-12-05
製品の特徴
PRODUCT MONOGRAPH
CLARITIN
® LIQUID CAPSULES LORATADINE CAPSULES, 10 MG
HISTAMINE H
1
RECEPTOR ANTAGONIST
Bayer Inc.
DATE OF PREPARATION:
2920 Matheson Blvd. E
May 10
th
, 2019
Mississauga, ON
L4W 5R6
Control #: 225631
® TM see www.bayer.ca/tm-mc
_ _
_CLARITIN LIQUID CAPSULES _
_Page 2 of 22_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
………………………………….…...
3
SUMMARY PRODUCT INFORMATION
...........................................................................
3
INDICATIONS AND CLINICAL
USE.................................................................................
3
CONTRAINDICATIONS
......................................................................................................
3
WARNINGS AND PRECAUTIONS
....................................................................................
3
ADVERSE REACTIONS
......................................................................................................
4
DRUG INTERACTIONS
.......................................................................................................
6
DOSAGE AND ADMINISTRATION
...................................................................................
7
OVERDOSAGE
.....................................................................................................................
7
ACTION AND CLINICAL PHARMACOLOGY
................................................................. 7
STORAGE AND STABILITY
..............................................................................................
8
SPECIAL HANDLING INSTRUCTIONS
............................................................................
8
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 9
PART II: SCIENTIFIC INFORMATION
…………………………………………………….
. 10
PHARMACEUTICAL INFORMATION
............................................................................
10
CLINICAL
TRIALS...........................................................
完全なドキュメントを読む
